Edit
Sunesis Pharmaceuticals, Inc.
http://www.sunesis.com/Last activity: 11.03.2021
Probably Closed - Reference to Viracta Therapeutics, Inc.
Biopharmaceutical company developing oncology therapeutics for the treatment of solid and hematologic cancers
Location: United States, California, San Francisco
Total raised: $25M
Investors 7
Funding Rounds 1
| Date | Series | Amount | Investors |
| 11.07.2019 | - | $25M | - |
Mentions in press and media 16
| Date | Title | Description |
| 16.02.2021 | Viracta Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering the Use of its Combination Product Candidate for the Treatment of Epstein-Barr Virus-associated Lymphoma | |
| 07.12.2020 | Viracta Therapeutics Announces Presentation of Updated Phase 2 Data at ASH 2020 and Productive Outcome of its Recent End of Phase 2 Meeting with the FDA | |
| 11.07.2019 | Sunesis Announces Pricing of $25 Million Offering of Securities | SOUTH SAN FRANCISCO, Calif., July 10, 2019 (GLOBE NEWSWIRE) — Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced the pricing of underwritten public offerings of (i) 33,333,667 shares of its common stock and (ii) 8,333 shares of it... |
| 13.06.2016 | Sunesis Pharmaceuticals Announces Positive Results from Trial in Frontline Elderly AML and MDS | South San Francisco, CA, — Sunesis Pharmaceuticals (NASDAQ:SNSS) today announced the presentation of updated results from an ongoing Phase 1b/2 University of Texas MD Anderson Cancer Center-sponsored trial of vosaroxin in combination with d... |
| 31.05.2015 | Sunesis Pharmaceuticals Presents VALOR Trial Subgroup Analysis at ASCO 2015 Annual Meeting | South San Francisco, CA — Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced results from a post hoc subgroup analysis of patients age 60 years and older who underwent allogeneic hematopoietic cell transplant (HCT) in the VALOR tri... |
| 08.12.2014 | Sunesis Presents Positive Updated Results from Ongoing Vosaroxin Trial at ASH Annual Meeting | South San Francisco, CA — Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the presentation of updated results from an ongoing Phase 1b/2 University of Texas MD Anderson Cancer Center-sponsored trial of vosaroxin in combination w... |
| 24.11.2014 | Sunesis Announces Publication of REVEAL-1 Trial Results in the British Journal of Haematology | South San Francisco, CA — Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the publication of results from the Company’s REVEAL-1 (Response Evaluation of Vosaroxin in Elderly AmL) trial, a Phase 2 trial of single agent vosaroxin ... |
| 19.11.2014 | Sunesis Announces Publication of Vosaroxin Phase 1b/2 AML Trial Results in Haematologica | South San Francisco, CA — Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the online publication of results from the Company’s Phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory ... |
| 06.10.2014 | Sunesis Announces Results From Pivotal Phase 3 VALOR Trial of Vosaroxin and Cytarabine | South San Francisco, CA — Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced results from the pivotal Phase 3 VALOR trial, a randomized, double-blind, placebo-controlled trial of vosaroxin and cytarabine in patients with first rela... |
| 09.07.2014 | Sunesis Pharmaceuticals Announces European Medicines Agency Acceptance of Pediatric Investigation Plan for Qinprezo(TM) (Vosaroxin) for AML | South San Francisco, CA — Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the Pediatric Committee of the European Medicines Agency (EMA) has issued a positive opinion on the Company’s Pediatric Investigation Plan (PIP) for ... |
Show more